These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 21651893)
1. Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline. Wang D; Yang L; Su J; Niu Y; Lei X; Xiong J; Cao X; Hu Y; Mei B; Hu JF Biochem Biophys Res Commun; 2011 Jul; 410(2):229-34. PubMed ID: 21651893 [TBL] [Abstract][Full Text] [Related]
2. Xanomeline derivative EUK1001 attenuates Alzheimer's disease pathology in a triple transgenic mouse model. Li Z; Jia K; Duan Y; Wang D; Zhou Z; Dong S Mol Med Rep; 2017 Nov; 16(5):7835-7840. PubMed ID: 28944835 [TBL] [Abstract][Full Text] [Related]
3. Ibuprofen partially attenuates neurodegenerative symptoms in presenilin conditional double-knockout mice. Dong Z; Yan L; Huang G; Zhang L; Mei B; Meng B Neuroscience; 2014 Jun; 270():58-68. PubMed ID: 24699228 [TBL] [Abstract][Full Text] [Related]
4. A novel derivative of xanomeline improves fear cognition in aged mice. Si W; Zhang X; Niu Y; Yu H; Lei X; Chen H; Cao X Neurosci Lett; 2010 Apr; 473(2):115-9. PubMed ID: 20178835 [TBL] [Abstract][Full Text] [Related]
5. Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice. Gu F; Zhu M; Shi J; Hu Y; Zhao Z Neurosci Lett; 2008 Jul; 440(1):44-8. PubMed ID: 18539391 [TBL] [Abstract][Full Text] [Related]
6. A novel derivative of xanomeline improved memory function in aged mice. Cui YH; Si W; Yin L; An SM; Jin J; Deng SN; Cao XH Neurosci Bull; 2008 Aug; 24(4):251-7. PubMed ID: 18668154 [TBL] [Abstract][Full Text] [Related]
7. Calorie restriction ameliorates neurodegenerative phenotypes in forebrain-specific presenilin-1 and presenilin-2 double knockout mice. Wu P; Shen Q; Dong S; Xu Z; Tsien JZ; Hu Y Neurobiol Aging; 2008 Oct; 29(10):1502-11. PubMed ID: 17499883 [TBL] [Abstract][Full Text] [Related]
8. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. Mirza NR; Peters D; Sparks RG CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557 [TBL] [Abstract][Full Text] [Related]
9. Increased oxidative stress and astrogliosis responses in conditional double-knockout mice of Alzheimer-like presenilin-1 and presenilin-2. Zhu M; Gu F; Shi J; Hu J; Hu Y; Zhao Z Free Radic Biol Med; 2008 Nov; 45(10):1493-9. PubMed ID: 18822370 [TBL] [Abstract][Full Text] [Related]
11. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Fisher A; Heldman E; Gurwitz D; Haring R; Karton Y; Meshulam H; Pittel Z; Marciano D; Brandeis R; Sadot E; Barg Y; Pinkas-Kramarski R; Vogel Z; Ginzburg I; Treves TA; Verchovsky R; Klimowsky S; Korczyn AD Ann N Y Acad Sci; 1996 Jan; 777():189-96. PubMed ID: 8624083 [TBL] [Abstract][Full Text] [Related]
12. Classics in Chemical Neuroscience: Xanomeline. Bender AM; Jones CK; Lindsley CW ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924 [TBL] [Abstract][Full Text] [Related]
13. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903 [TBL] [Abstract][Full Text] [Related]
14. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348 [TBL] [Abstract][Full Text] [Related]
15. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268 [TBL] [Abstract][Full Text] [Related]
16. Increased inflammatory response both in brain and in periphery in presenilin 1 and presenilin 2 conditional double knock-out mice. Jiang X; Zhang D; Shi J; Chen Y; Zhang P; Mei B J Alzheimers Dis; 2009; 18(3):515-23. PubMed ID: 19584449 [TBL] [Abstract][Full Text] [Related]
17. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749 [TBL] [Abstract][Full Text] [Related]
18. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Woolley ML; Carter HJ; Gartlon JE; Watson JM; Dawson LA Eur J Pharmacol; 2009 Jan; 603(1-3):147-9. PubMed ID: 19111716 [TBL] [Abstract][Full Text] [Related]
19. Trans-cinnamaldehyde improves neuroinflammation-mediated NMDA receptor dysfunction and memory deficits through blocking NF-κB pathway in presenilin1/2 conditional double knockout mice. Zhao Y; Deng H; Li K; Wang L; Wu Y; Dong X; Wang X; Chen Y; Xu Y Brain Behav Immun; 2019 Nov; 82():45-62. PubMed ID: 31376499 [TBL] [Abstract][Full Text] [Related]
20. M Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]